DDX58 antibody (AA 203-925)

Catalog No. ABIN7872088

The Rabbit Polyclonal anti-DDX58 antibody (ABIN7872088) specifically detects DDX58 in WB, ELISA, IHC and FACS. The antibody is reactive with Human samples.

Quick Overview for DDX58 antibody (AA 203-925) (ABIN7872088)

Target: DDX58 (DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 58 (DDX58))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This DDX58 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Product Details anti-DDX58 Antibody

Binding Specificity: AA 203-925

Purpose: RIGI Antibody / DDX58

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human DDX58/RIG-1 recombinant protein (Position: K203-K925) was used as the immunogen for the RIGI antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the RIGI antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the RIGI antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for DDX58

Target: DDX58 (DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 58 (DDX58))

Alternative Name: RIGI

Background: RIGI antibody detects Retinoic acid-inducible gene I protein, encoded by the DDX58 gene on chromosome 9p21. RIGI antibody is widely applied in studies of innate immunity, antiviral defense, and RNA sensing pathways. RIG-I is a cytoplasmic pattern recognition receptor (PRR) belonging to the RIG-I-like receptor (RLR) family, which also includes MDA5 and LGP2. RIG-I detects viral double-stranded RNA with 5'-triphosphate ends and initiates signaling cascades that activate interferon production and antiviral gene expression. Expression is inducible by interferons and viral infection, and is present in a wide range of cell types, especially immune cells and epithelial cells.

Structurally, RIG-I contains two N-terminal caspase activation and recruitment domains (CARDs), a central DExD/H-box helicase domain, and a C-terminal regulatory domain that binds RNA. The CARD domains recruit downstream adaptors, while the helicase and regulatory domains bind viral RNA. Conformational changes upon RNA binding expose the CARDs, enabling signaling activation. Post-translational modifications such as ubiquitination regulate RIG-I activation and turnover.

Functionally, RIG-I is a critical sensor of viral RNA. Upon binding RNA ligands, it interacts with the mitochondrial antiviral signaling protein (MAVS), initiating signaling through TBK1, IKK epsilon, and IRF3/7, leading to type I interferon production. This antiviral program restricts replication of RNA viruses including influenza, vesicular stomatitis virus, and hepatitis C virus. RIG-I also influences adaptive immunity by modulating dendritic cell maturation and antigen presentation. Researchers employ RIGI antibody to study innate immune sensing, interferon biology, and antiviral responses.

Clinically, RIG-I is associated with autoimmune disorders, infectious disease, and cancer. Gain-of-function mutations in DDX58 cause Singleton-Merten syndrome, an autoinflammatory disease with vascular calcification and lupus-like features. Aberrant RIG-I signaling contributes to chronic inflammation and autoimmunity, while defective responses increase susceptibility to viral infections. RIG-I also acts as a tumor suppressor by promoting cell death and interferon responses, but tumors may evade RIG-I signaling. NSJ Bioreagents offers RIGI antibody to support immunology, virology, and oncology research.

Experimentally, RIGI antibody is used in western blotting to detect the ~102 kDa protein, in immunofluorescence to study cytoplasmic localization, and in immunohistochemistry to evaluate expression in infected or immune tissues. Co-immunoprecipitation with RIGI antibody identifies MAVS and signaling partners, enabling dissection of antiviral pathways.

UniProt: O95786

Pathways: Activation of Innate immune Response, Hepatitis C